0001209191-24-000807.txt : 20240104
0001209191-24-000807.hdr.sgml : 20240104
20240104164135
ACCESSION NUMBER: 0001209191-24-000807
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240102
FILED AS OF DATE: 20240104
DATE AS OF CHANGE: 20240104
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Nolan Sean P.
CENTRAL INDEX KEY: 0001569926
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39536
FILM NUMBER: 24512708
MAIL ADDRESS:
STREET 1: C/O INTERMUNE, INC.
STREET 2: 3280 BAYSHORE BLVD.
CITY: BRISBANE
STATE: CA
ZIP: 94005
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Taysha Gene Therapies, Inc.
CENTRAL INDEX KEY: 0001806310
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 843199512
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 3000 PEGASUS PARK DRIVE
STREET 2: SUITE 1430
CITY: DALLAS
STATE: TX
ZIP: 75247
BUSINESS PHONE: (214) 612-0000
MAIL ADDRESS:
STREET 1: 3000 PEGASUS PARK DRIVE
STREET 2: SUITE 1430
CITY: DALLAS
STATE: TX
ZIP: 75247
4
1
doc4.xml
FORM 4 SUBMISSION
X0508
4
2024-01-02
0
0001806310
Taysha Gene Therapies, Inc.
TSHA
0001569926
Nolan Sean P.
C/O TAYSHA GENE THERAPIES, INC.
3000 PEGASUS PARK DRIVE, SUITE 1430
DALLAS
TX
75247
1
1
0
0
Chief Executive Officer
0
Common Stock
2024-01-02
4
A
0
1184688
0.00
A
1185858
D
Common Stock
1535545
I
See Footnote
Employee Stock Option (right to buy)
1.71
2024-01-02
4
A
0
1184688
0.00
A
2034-01-02
Common Stock
1184688
1184688
D
Represents a restricted stock unit ("RSU") award. The RSUs will vest in four equal annual installments beginning on January 2, 2025, subject to the Reporting Person's continuous service through each applicable vesting date.
The securities are held by Nolan Capital, LLC (the "LLC"). The Reporting Person is the President of the LLC and has shared voting and investment power with respect to the shares held by the LLC.
25% of the total number of shares underlying the option shall vest and become exercisable on January 2, 2025 and the remainder shall vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service through each applicable vesting date.
/s/ Kamran Alam, Attorney-in-Fact
2024-01-04